Hanmi Seeking More Deals After Record Lilly Tie-Up
This article was originally published in PharmAsia News
Executive Summary
After clinching the biggest ever license deal by a South Korean pharma firm, with Lilly for its oral Bruton's tyrosine kinase (BTK) inhibitor earlier this year, Hanmi Pharm is making efforts to reach more agreements for its other drug candidates.